{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:08:34Z","timestamp":1740136114543,"version":"3.37.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pan.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T17:28:25Z","timestamp":1711387705000},"page":"600-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-6939","authenticated-orcid":false,"given":"Cheng-Yu","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-8264","authenticated-orcid":false,"given":"Chung-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Yeh","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sz-Chi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-4077","authenticated-orcid":false,"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Chuan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Jui","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Ming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Jan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2743-9702","authenticated-orcid":false,"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-4548","authenticated-orcid":false,"given":"Wen-Chi","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"Cancer registry annual report of Taiwan in 2018","key":"10.1016\/j.pan.2024.03.014_bib1"},{"issue":"3","key":"10.1016\/j.pan.2024.03.014_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.pan.2024.03.014_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pan.2024.03.014_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01176","article-title":"Real world evidence on second-line palliative chemotherapy in advanced pancreatic cancer","volume":"10","author":"Gr\u00e4nsmark","year":"2020","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.pan.2024.03.014_bib5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib6","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cam4.2094","article-title":"Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: a 7-year multicenter observational cohort study in Taiwan","volume":"8","author":"Lai","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.pan.2024.03.014_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.10.023","article-title":"A\u00a0multicenter, phase I\/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study","volume":"124","author":"Chiang","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pan.2024.03.014_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2022.06.043","article-title":"A\u00a0prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - the Taiwan Cooperative Oncology Group T1217 study","volume":"173","author":"Bai","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10018","key":"10.1016\/j.pan.2024.03.014_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2024.03.014_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","article-title":"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience","volume":"18","author":"Glassman","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2024.03.014_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919871126","article-title":"Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group","volume":"11","author":"Yoo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib12","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1038\/s41598-020-64421-6","article-title":"The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort","volume":"10","author":"Su","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pan.2024.03.014_bib13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.21037\/apm-20-45","article-title":"Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"16","key":"10.1016\/j.pan.2024.03.014_bib14","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2024.03.014_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211058255","article-title":"Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study","volume":"13","author":"Chiu","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.pan.2024.03.014_bib17","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1002\/cam4.5714","article-title":"Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.pan.2024.03.014_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jhbp.1128","article-title":"Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin","volume":"29","author":"Chiu","year":"2022","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.pan.2024.03.014_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211003053","article-title":"Clinical outcomes of liposomal irinotecan plus fluorouracil\/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy","volume":"13","author":"Bang","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib20","article-title":"Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: a real-world multicenter study","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010057","article-title":"Prognostic factors for advanced pancreatic cancer treated with gemcitabine plus S-1: retrospective analysis and development of a prognostic model","volume":"11","author":"Chang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.pan.2024.03.014_bib22","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/bjc.2017.128","article-title":"Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data","volume":"116","author":"Hamada","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2024.03.014_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cam4.2705","article-title":"Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis","volume":"9","author":"Chan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.pan.2024.03.014_bib24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s12094-020-02473-w","article-title":"Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting","volume":"23","author":"Franco","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12885-016-2798-8","article-title":"Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)","volume":"16","author":"Vogel","year":"2016","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.pan.2024.03.014_bib26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.pan.2024.03.014_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.mcg.0000225657.30803.9d","article-title":"Survival and prognostic factors of unresectable pancreatic cancer","volume":"42","author":"Park","year":"2008","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.pan.2024.03.014_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46924-0","article-title":"Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer","volume":"13","author":"Fukahori","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.pan.2024.03.014_bib29","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/CMAR.S196300","article-title":"Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016","volume":"11","author":"Chou","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"9","key":"10.1016\/j.pan.2024.03.014_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.5306\/wjco.v12.i9.787","article-title":"Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer","volume":"12","author":"Blomstrand","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2022.06.042","article-title":"Impact of first-line FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: evidence from the prospective international multicentre PURPLE pancreatic cancer registry","volume":"174","author":"Santucci","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.pan.2024.03.014_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16199","article-title":"Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"5","author":"Klein-Brill","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pan.2024.03.014_bib33","doi-asserted-by":"crossref","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","article-title":"1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II\/III trial","volume":"34","author":"Ohba","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.pan.2024.03.014_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3892\/mco.2023.2694","article-title":"Real-world treatment outcomes among patients with metastatic pancreatic cancer in Japan: the Tokushukai real-world data project","volume":"19","author":"Shimoyama","year":"2023","journal-title":"Mol Clin Oncol"},{"issue":"10409","key":"10.1016\/j.pan.2024.03.014_bib35","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2024.03.014_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119539","article-title":"A\u00a0real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma","volume":"14","author":"Chun","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1186\/s12885-021-08887-1","article-title":"Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study","volume":"21","author":"Park","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2024.03.014_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919853196","article-title":"A\u00a0real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid","volume":"11","author":"Kieler","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pan.2024.03.014_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-023-10542-w","article-title":"Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil\/leucovorin","volume":"23","author":"Kawakami","year":"2023","journal-title":"BMC Cancer"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:23:26Z","timestamp":1736454206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390324000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1424390324000760"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2024.03.014","relation":{},"ISSN":["1424-3903"],"issn-type":[{"type":"print","value":"1424-3903"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 IAP and EPC. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}